Summary of He Yuan Bio's Conference Call Company Overview - He Yuan Bio specializes in the research and development of plant-derived recombinant protein expression technology and products, established in 2006 as a national high-tech enterprise [2][3]. Core Product - The core product, HY1,001 (recombinant human serum albumin), was launched in China on July 18, 2025, for treating hypoalbuminemia due to liver cirrhosis. It has completed Phase II clinical trials in the U.S. and is advancing to Phase III [2][3][8]. Market Potential - Expected revenue from HY1,001 is projected to exceed 3 billion yuan by 2030, with a market share of approximately 39% in the recombinant human serum albumin market [4][19]. - The global market for human serum albumin (excluding China) is anticipated to grow from $4.643 billion in 2024 to $7.4 billion by 2031, with a CAGR of about 6.28%. The Chinese market is expected to grow from 39.5 billion yuan in 2024 to 57 billion yuan by 2030, with a CAGR of approximately 6% [2][10]. Production Advantages - He Yuan Bio utilizes rice endosperm cells as bioreactors, offering several advantages: 1. High recombinant protein expression (20-30 grams per kilogram of brown rice) [5]. 2. Simple purification process, leading to lower costs (production cost is at least 50% lower than traditional methods) [5][18]. 3. Easy scalability, with raw materials that can be stored for 2-3 years at room temperature [5]. 4. Good safety profile, with no risk of transmitting animal-borne diseases [5][18]. Production Capacity and Infrastructure - A 10-ton capacity human serum albumin raw material factory is operational, with a new intelligent production line of 120 tons per year set to begin construction in September 2024 [7]. - A transgenic rice planting base in Xinjiang is expected to cover over 9,000 acres by 2025, with plans to expand to 20,000 acres by 2026 and 35,000 acres by 2027 [7]. Competitive Landscape - The domestic human serum albumin market is heavily reliant on plasma purification, with 60% of supply imported. In 2021, China had only 290 plasma collection stations compared to 1,041 in the U.S. [4][11][12]. - Major competitors include Tian Tan Bio and Hua Lan Bio, with Tian Tan being the largest producer, collecting 2,781 tons of plasma in 2024 [15][16]. Risks - He Yuan Bio faces potential legal risks, including a patent investigation initiated by Virtual BioScience in December 2020, which has since been withdrawn. However, He Yuan Bio has filed a counter-infringement lawsuit [5][6]. Future Outlook - The company is optimistic about expanding its product pipeline, with additional products like HY1,002 and HY1,003 in development, targeting various medical conditions [21][22]. - Despite current financial losses, the high R&D investment is expected to position the company favorably for future growth, with a projected peak sales value of 9.8 billion yuan by 2030 [20].

Company Overview - He Yuan Bio, established in 2006, specializes in the research and development of plant-derived recombinant protein expression technology and products, aiming to create world-class biopharmaceuticals based on plant bioreactor technology [5]. - The company has developed two core technology platforms: a high-efficiency recombinant protein expression platform and a protein purification platform, achieving a recombinant protein expression yield of 20-30g/kg and a purification purity of 99.9999% [14][19]. Product Pipeline - The core product, HY1001 (recombinant human albumin), is expected to receive domestic approval by July 2025 and has completed FDA Type C communication for its Phase III clinical trial design in the U.S. [2][27][28]. - Other products in the pipeline include HY1002 (lactoferrin lysozyme oral solution), HY1003 (α-1 antitrypsin), and additional candidates targeting various medical conditions, with a total of 19 recombinant proteins under development [2][25]. Market and Competition - The domestic human recombinant albumin market is projected to grow from 39.5 billion RMB in 2024 to 57 billion RMB by 2030, with a CAGR of 6% [3][41]. - Currently, 62.9% of the domestic market is supplied by imports, with He Yuan Bio positioned as a leading domestic player in the recombinant HSA market, indicating strong potential for import substitution [3][42]. - The global demand for HSA is expected to reach 800 tons by 2030, with emerging markets heavily reliant on imports [3][41]. Cost and Production Advantages - The production cost of HY1001 is projected to be significantly lower than that of plasma-derived human albumin, with estimates suggesting a cost reduction of over 50% once the 120-ton production line is fully operational [54][56]. - The company has established a commercial-scale production line capable of producing 10 tons of HSA per year and is expanding to a 120-ton capacity by 2024 [22]. Clinical and Regulatory Progress - HY1001 has shown non-inferiority to plasma-derived human albumin in clinical trials, demonstrating comparable efficacy and safety profiles [52][49]. - The product has been recognized by FDA experts as a "historical innovation," supporting its global clinical trial design [28]. Future Outlook - The market for recombinant human albumin is expected to expand significantly, with projected sales revenue for HY1001 reaching approximately 15.67 billion RMB by 2030, driven by increasing treatment rates for liver cirrhosis and low albumin levels [58]. - The company anticipates a growing demand for its products, particularly in light of the limitations of plasma-derived products and the increasing focus on safety and supply stability [45][47].

Core Viewpoint - The company is initiating a non-public offering plan to raise up to 1.5 billion yuan, with 1.2 billion yuan allocated for a smart industrial base project capable of processing 1,200 tons of plasma annually, amidst increasing industry competition and declining performance [1] Group 1: Capacity and Plasma Source Gap - The planned smart factory aims for an annual plasma processing capacity of 1,200 tons, but the company currently has only 9 plasma collection stations, leading to an estimated plasma collection of only 1,180 tons by 2033, resulting in a shortfall of approximately 700 tons post-project completion [2] - The approval process for new plasma collection stations is becoming increasingly stringent, and the company needs to secure approvals for 8 new stations and identify acquisition targets, making plasma source expansion challenging [2] - The total investment for the project is 2.308 billion yuan, with a construction period of 4.5 years, leaving a funding gap of over 1.1 billion yuan even if the 1.2 billion yuan is successfully raised [2] Group 2: Production and Sales Imbalance - In 2024, the company is facing difficulties in capacity digestion, with a 24.72% increase in blood product production but a 5.42% decrease in sales, leading to a more than 70% increase in inventory, reaching 2.2651 million bottles [3] - The blood product industry has entered a competitive phase with large-scale production capabilities, with leading companies like Tian Tan Biological, Shanghai Raist, and Hualan Biological having established or are in the process of building large production bases, often ahead of the company [3] - Since 2025, the industry has seen a decline in net profits for several companies due to falling product prices, indicating increasing pressure from price wars [3] Group 3: Performance Decline and Expansion Timing - The company is experiencing a significant decline in performance, with a 7.4% year-on-year decrease in revenue and a 13.6% drop in net profit attributable to shareholders in the first three quarters of 2025, including a 31.06% year-on-year plunge in net profit for the third quarter [4] - Accounts receivable have increased by 32.1%, and credit impairment losses have surged by 411%, while the expense ratio has risen across the board, further squeezing profit margins [4] - The question of whether large-scale expansion can be supported by sufficient market foundation and operational capability is becoming a focal point for investors amid ongoing performance pressures [4]

Group 1: International Medicine - International Medicine plans to raise up to approximately 1.008 billion yuan through a private placement of A-shares to no more than 35 specific investors [1] - The raised funds will be allocated to three main projects: Smart Health and Elderly Care project (total investment of about 751 million yuan, with approximately 638 million yuan from the raised funds), Phase II of the Proton Therapy Center (total investment of 99.93 million yuan, with 99.93 million yuan from the raised funds), and working capital (total investment of 270 million yuan, with 270 million yuan from the raised funds) [1] Group 2: Zhongtai Securities - Zhongtai Securities reports that the innovative drug sector remains the most important theme in the pharmaceutical industry, with recent adjustments leading to a more reasonable valuation and increased safety margins [2] - The report suggests that the innovative drug sector has entered a favorable allocation window following a correction, and highlights structural rotation opportunities within the sector [2] Group 3: Zhongsheng Pharmaceutical - Zhongsheng Pharmaceutical's subsidiary has received approval for clinical trials of the innovative peptide drug RAY1225 for the treatment of Metabolic Associated Steatotic Hepatitis (MASH) [3] - The approval is significant as there are currently no approved drugs for this condition in the domestic market, indicating a clear market demand and considerable potential [3] Group 4: Tiantan Biological - Tiantan Biological's "Human Prothrombin Complex" has completed Phase III clinical trials, showing significant improvement in coagulation factor levels and bleeding symptoms in patients with Hemophilia B [4] - The positive results from the clinical trials provide a critical foundation for the product's market application, marking an important advancement in the field of blood products [4]

Core Viewpoint - Tian Tan Biological announced the completion of Phase III clinical trials for its "Prothrombin Complex Concentrate," which shows significant efficacy in treating hemophilia B and related coagulation disorders [1] Group 1: Clinical Trial Results - The Prothrombin Complex Concentrate is designed to treat congenital and acquired deficiencies of coagulation factors II, VII, IX, and X, including hemophilia B, anticoagulant overdose, and vitamin K deficiency [1] - Clinical trial results indicate that the infusion of this product significantly increases the levels of coagulation factors II, VII, IX, and X in hemophilia B patients, thereby improving their coagulation function and alleviating bleeding symptoms [1]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

证券代码：600161 证券简称：天坛生物 公告编号：2025-056 北京天坛生物制品股份有限公司 关于下属企业获得临床试验总结报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、国内市场情况： | 企业名称 上海莱士血液制品股份有限公司 | 规格 200IU/瓶、300IU/瓶 | 剂型 | | --- | --- | --- | | 华兰生物工程股份有限公司 | 100IU/瓶、200IU/瓶、300IU/瓶、400IU/瓶、1000IU/瓶 | | | 诺一生物医药股份有限公司 | 200IU/瓶、300IU/瓶、400IU/瓶 | | | 贵州泰邦生物制品有限公司 | 300IU/瓶 | | | 山东泰邦生物制品有限公司 | 300IU/瓶 | | | 南岳生物制药有限公司 | 200IU/瓶、300IU/瓶 | | | 山西康宝生物制品股份有限公司 | 300IU/瓶 | | | 博晖生物制药（河北）有限公司 | 300IU/瓶 | | | 广东卫伦生物制药有限公司 | 300IU/瓶 | 注射剂 | ...

Core Viewpoint - Tiantan Biological (600161.SH) announced that its subsidiary, Guizhou Biological Pharmaceutical Co., Ltd., has completed Phase III clinical trials for "Prothrombin Complex Concentrate" and received the clinical trial summary report [1] Group 1: Clinical Trial Results - The clinical trial results indicate that the Prothrombin Complex Concentrate significantly enhances coagulation factor levels II/VII/IX/X in patients with Hemophilia B [1] - The treatment improves coagulation function and alleviates bleeding symptoms and signs in patients with Hemophilia B, demonstrating good efficacy [1] - Safety analysis results show that the drug has a favorable safety profile during clinical application for patients with Hemophilia B [1]

Core Viewpoint - TianTan Biological (600161.SH) announced that its subsidiary, Guizhou Biological Pharmaceutical Co., Ltd., has completed Phase III clinical trials for "Prothrombin Complex Concentrate" and received the clinical trial summary report [1] Group 1: Clinical Trial Results - The clinical trial results indicate that the Prothrombin Complex Concentrate significantly enhances coagulation factor levels II/VII/IX/X in patients with Hemophilia B [1] - The treatment improves coagulation function and alleviates bleeding symptoms and signs in patients with Hemophilia B, demonstrating good efficacy [1] Group 2: Safety Analysis - Safety analysis results show that the drug has a good safety profile during clinical application for patients with Hemophilia B [1]

Core Viewpoint - Tiantan Biological announced that its subsidiary Tiantan Guizhou has completed Phase III clinical trials for "Prothrombin Complex Concentrate," which is primarily used to treat congenital and acquired coagulation factor deficiencies, including Hemophilia B [1] Group 1 - The clinical trial results indicate that the drug significantly improves coagulation factor levels in patients with Hemophilia B and alleviates bleeding symptoms, demonstrating good efficacy and safety [1] - The research and development investment for this product amounted to 42.3963 million yuan [1] - Tiantan Guizhou plans to submit a registration application to the National Medical Products Administration, although the review timeline and the issuance of the drug registration certificate remain uncertain [1] Group 2 - Once approved, the product will be eligible for production and market sales [1]